Aurinia Call on Phase 2 Results for Dry Eye Med

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it will report results before the opening of trading and hold a webcast and conference call to discuss the results of its Phase 2, double-masked, head-to-head study of VOS 0.2% versus Restasis® (cyclosporine ophthalmic emulsion 0.05%) to evaluate the efficacy, safety and tolerability at four weeks in subjects with dry eye syndrome (DES).

Aurinia will host a conference call and webcast presentation at 8:00am ET on Tuesday, January 22, 2019. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under “News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

https://www.biospace.com/article/releases/aurinia-to-hold-conference-call-and-webcast-to-discuss-results-of-phase-2-head-to-head-study-of-voclosporin-ophthalmic-solution-versus-restasis-for-the-treatment-of-dry-eye-syndrome/